BusinessExosome Diagnostics Launches National Sales Team to Support Flagship Test, ExoDx®Prostate(IntelliScore)By Nasdaq OMXJan 3, 2018, 12:31 PM UTC
BusinessExosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider NetworkBy Nasdaq OMXDec 4, 2017, 12:33 PM UTC
BusinessExosome Diagnostics Announces National Medicare Reimbursement Rate Set at $760 for its Prostate Cancer IntelliScore TestBy Nasdaq OMXNov 27, 2017, 1:16 PM UTC
BusinessTelix Pharmaceuticals and ANMI Partner for Prostate Cancer ImagingBy Nasdaq OMXOct 23, 2017, 11:00 PM UTC
BusinessHIFU for Prostate Cancer now Available at North Carolina Specialty Hospital in Durham, North CarolinaBy Nasdaq OMXSep 13, 2017, 4:54 PM UTC
BusinessHeart Attack, Breast Cancer, and Prostate Cancer Patterns Detected in Urine before Diagnosis According to Article in the Journal of American Physicians and SurgeonsBy Nasdaq OMXSep 6, 2017, 2:19 PM UTC
BusinessCareFirst BlueCross BlueShield and Exosome Diagnostics Announce Evidence Development Collaboration for Molecular Diagnostic TestsBy Nasdaq OMXAug 24, 2017, 12:59 PM UTC
BusinessTempus Selected as Sequencing and Analytics Provider by the Prostate Cancer Clinical Trials Consortium for Phase II Clinical TrialBy Nasdaq OMXAug 17, 2017, 1:00 PM UTC
